Pharmacokinetic-pharmacodynamic modelling of ketamine in six neurotraumatised intensive care patients

Clinical Drug Investigation

Volumn 23, Issue 9, 2003, Pages 605-609

  Hijazi, Youssef ^a,b   Bodonian, Carole ^b   Salord, François ^b   Bressolle, Françoise ^c   Boulieu, Roselyne ^a,b  

^a UNIVERSITÉ LYON 1   (France)

^b HÔPITAL NEUROLOGIQUE   (France)

^c UNIV MONTPELLIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

KETAMINE; SEDATIVE AGENT;

ADULT; ARTICLE; BOLUS INJECTION; CLINICAL ARTICLE; CONTROLLED STUDY; CRITICAL ILLNESS; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG ELIMINATION; FEMALE; GLASGOW COMA SCALE; HUMAN; INTENSIVE CARE; MALE; NERVOUS SYSTEM INJURY; PAIN; PRIORITY JOURNAL; SEDATION;

EID: 0141724919     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200323090-00007     Document Type: Article

References (17)

1. White PF, Way WL, Trevor AJ. Ketamine: its pharmacology and therapeutic uses. Anesthesiology 1982; 56: 119-36
2. Nimmo WS, Clements JA. Ketamine on demand for postoperative analgesia [letter]. Anaesthesia 1981; 36: 826
3. Kolenda H, Gremmelt A, Rading S, et al. Ketamine for analgosedative therapy in intensive care treatment of head injured patients. Acta Neurochir (Wien) 1996; 138: 1193-9
4. Marcoux FX, Goodrich JE, Dominick MA. Ketamine prevents ischemic neuronal injury. Brain Res 1988; 452: 329-55
5. Schwedler M, Miletich DJ, Albrecht RF. Cerebral blood flow and metabolism following ketamine administration. Can Anaesth Soc J 1982; 29: 222-6
6. Pfenninger E, Grunert A, Bowdler I, et al. The effect of ketamine on intracranial pressure during haemorrhagic shock under conditions of both spontaneous breathing and controlled ventilation. Acta Neurochir (Wien) 1985; 78: 113-8
7. Mayberg TS, Lam AM, Domino KB, et al. Cerebral blood flow velocity and ADVO2 response to ketamine in neurosurgical patients [abstract]. Anesthesiology 1993; 79: A204
8. Mirski MA, Muffelman B, Ulatowski JA, et al. Sedation for the critically ill neurologic patient. Crit Care Med 1995; 23: 2038-53
9. Ravussin P, Marty J, Boulard G, et al. Le réveil en neurochirurgie. Ann Fr Anesth Reanim 1992; 11: 677-81
10. Schüttler J, Stanski DR, White PF, et al. Pharmacodynamic modelling of the EEG effects of ketamine and its enantiomers in man. J Pharmacokinet Biopharm 1987; 15 (3): 241-53
11. Devlin JW, Fraser GL, Kanji S, et al. Sedation assessment in critically ill adults. Ann Pharmacother 2001; 35: 1624-32
12. Hijazi Y, Bodonian C, Bolon M, et al. Pharmacokinetics and haemodynamics of ketamine in intensive care patients with brain or spinal cord injury. Br J Anaesth 2003; 90: 155-60
13. Bolze S, Boulieu R. HPLC determination of ketamine, norketamine and dehydronorketamine in plasma with a high purity reversed phase sorbent. Clin Chem 1998; 44: 560-4
14. Farenc C, Fabreguette JR, Bressolle F. Pk-fit: A pharmacokinetic/pharmacodynamic and statistical data analysis software. Comput Biomed Res 2000; 33: 315-29
15. Clements JA, Nimmo WS. Pharmacokinetics and analgesic effects of ketamine in man. Br J Anaesth 1981; 53: 27-30
16. Ihmsen H, Geisslinger G, Shiittler J. Stereoselective pharmacokinetics of ketamine: R(-) ketamine inhibits the elimination of S(+) ketamine. Clin Pharmacol Ther 2001; 70: 431-8
17. Geisslinger G, Hering W, Thomman P. et al. Pharmacokinetics and pharmacodynamics of ketamine enantiomers in surgical patients using a stereoselective analytical method. Br J Anaesth 1993; 70: 666-71